SCHEMBL2277157

SCHEMBL2277157

Fc1ccccc1-c1cc[nH]n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.53
NPC1 O15118 4/20 0.43
MPL P40238 1/20 0.43
DCUN1D1 Q96GG9 2/20 0.41
MAP4K1 Q92918 2/20 0.41
NOTUM Q6P988 1/20 0.41
NISCH Q9Y2I1 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
KDM5B Q9UGL1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497931 1.00 IDO1 (0.53) IDO1NPC1MPLDCUN1D1MAP4K1
SCHEMBL28005102 0.84 BCAT1 (0.38) IDO1DCUN1D1NOTUM
SCHEMBL4055200 0.81 GRK6 (0.39) IDO1DCUN1D1NOTUMCASP3SENP8
SCHEMBL3848065 0.77 F2RL3 (0.37) IDO1NPC1RAB9A
SCHEMBL3846622 0.76 ALPL (0.35) IDO1NPC1L3MBTL1CASP3SENP8
SCHEMBL988594 0.76 ALPL (0.48) IDO1NPC1RAB9A
SCHEMBL1176838 0.75 METAP2 (0.30)
SCHEMBL11624680 0.75 IDO1 (0.53) IDO1NPC1DCUN1D1NOTUMNISCH
SCHEMBL206363 0.75 IDO1 (0.53) IDO1NPC1DCUN1D1CASP3SENP8
SCHEMBL6693198 0.75 DCUN1D1 (0.41) IDO1DCUN1D1NISCHRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
EP-4229063-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME Therapeutics LLC (US) 2023-08-23 EP disclosed
CN-111630055-B Pyrazole-and indazole-substituted oxadiazolopyridine derivatives useful as ghrelin O-acyltransferase (GOAT) inhibitors 勃林格殷格翰国际有限公司 2023-07-14 CN disclosed
EP-4122929-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2023-01-25 EP disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed
EP-3746449-B1 PYRAZOLE- AND INDAZOLE-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2022-03-30 EP disclosed
US-20210380562-A1 Novel Compounds MISSION THERAPEUTICS LIMITED (GB) 2021-12-09 US disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
EP-1910348-A2 BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2008-04-16 EP disclosed
US-20070185175-A1 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 US disclosed
US-20070185175-A1 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 US disclosed
US-20070185175-A1 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 US disclosed
WO-2007016392-A2 BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-08 WO disclosed
WO-2007016392-A2 BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-08 WO disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed
US-4072498-A HERBICIDES THE UPJOHN COMPANY (US) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380562-A1 Novel Compounds USP30, USP20, USP10 IDO1 2211/4885NPC1 2862/4885MPL 4716/4885
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 IDO1 1352/4885NPC1 2611/4885MPL 2260/4885
US-20070185175-A1 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors GRK2, MAPK1, GRK4 IDO1 3131/4885NPC1 2260/4885MPL 1944/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 IDO1 4371/4885NPC1 1417/4885MPL 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.